Cy Fixen1, Jennifer Tunoa2. 1. University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. cy.fixen@cuanschutz.edu. 2. PGY2 Ambulatory Care Pharmacy Resident, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
Abstract
PURPOSE OF REVIEW: Authors review the safety and efficacy of romosozumab for the treatment of osteoporosis as demonstrated in three phase III clinical trials and offer insights into the potential cardiovascular risk associated with its use. RECENT FINDINGS: Incidence of new vertebral fracture is dramatically reduced with 12 months of romosozumab use in comparison to both placebo and active bisphosphonate control groups in patients with postmenopausal osteoporosis. Significant non-vertebral anti-fracture benefit was also demonstrated in patients with more severe osteoporosis. Numerical increases in cardiovascular events call into question the safety of romosozumab use, particularly in patients with cardiovascular history or at high cardiovascular risk. Romosozumab has impressive anti-fracture effects in postmenopausal women with high risk for fragility fracture. Despite no significant differences in baseline cardiovascular risk factors between groups, a numerical increase in serious cardiovascular adverse events was demonstrated with romosozumab in randomized trials with no discernable etiology. Until more real-world evidence is available, romosozumab should not be used in patients with a recent cardiovascular event and should be used cautiously in patients with high cardiovascular risk. Romosozumab's place in therapy is likely patients with severe postmenopausal osteoporosis and low cardiovascular risk.
PURPOSE OF REVIEW: Authors review the safety and efficacy of romosozumab for the treatment of osteoporosis as demonstrated in three phase III clinical trials and offer insights into the potential cardiovascular risk associated with its use. RECENT FINDINGS: Incidence of new vertebral fracture is dramatically reduced with 12 months of romosozumab use in comparison to both placebo and active bisphosphonate control groups in patients with postmenopausal osteoporosis. Significant non-vertebral anti-fracture benefit was also demonstrated in patients with more severe osteoporosis. Numerical increases in cardiovascular events call into question the safety of romosozumab use, particularly in patients with cardiovascular history or at high cardiovascular risk. Romosozumab has impressive anti-fracture effects in postmenopausal women with high risk for fragility fracture. Despite no significant differences in baseline cardiovascular risk factors between groups, a numerical increase in serious cardiovascular adverse events was demonstrated with romosozumab in randomized trials with no discernable etiology. Until more real-world evidence is available, romosozumab should not be used in patients with a recent cardiovascular event and should be used cautiously in patients with high cardiovascular risk. Romosozumab's place in therapy is likely patients with severe postmenopausal osteoporosis and low cardiovascular risk.
Authors: Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer Journal: N Engl J Med Date: 2016-09-18 Impact factor: 91.245
Authors: Paul D Miller; Gary Hattersley; Bente Juel Riis; Gregory C Williams; Edith Lau; Luis Augusto Russo; Peter Alexandersen; Cristiano A F Zerbini; Ming-yi Hu; Alan G Harris; Lorraine A Fitzpatrick; Felicia Cosman; Claus Christiansen Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul Journal: Hum Mol Genet Date: 2001-03-01 Impact factor: 6.150
Authors: M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan Journal: Am J Hum Genet Date: 2001-02-09 Impact factor: 11.025
Authors: Felicia Cosman; Daria B Crittenden; Serge Ferrari; E Michael Lewiecki; Juan Jaller-Raad; Cristiano Zerbini; Cassandra E Milmont; Paul D Meisner; Cesar Libanati; Andreas Grauer Journal: J Bone Miner Res Date: 2018-05-11 Impact factor: 6.741
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: E Michael Lewiecki; Tomasz Blicharski; Stefan Goemaere; Kurt Lippuner; Paul D Meisner; Paul D Miller; Akimitsu Miyauchi; Judy Maddox; Li Chen; Stephane Horlait Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Dongxing Zhu; Neil Charles Wallace Mackenzie; José Luis Millán; Colin Farquharson; Vicky Elizabeth MacRae Journal: PLoS One Date: 2011-05-17 Impact factor: 3.240